Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Absci Corporation is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and 2 distinct art units. This distribution indicates that the company's prosecution activity is spread across multiple technical sub-groups within the patent office. The involvement of 2 distinct art units suggests that the applications cover different specialized aspects of biotechnology.
RAGHU, GANAPATHIRAM is the busiest examiner for the portfolio, currently overseeing 1 busiest examiner pending office action. Although this examiner is the most active, the workload is evenly split, as the 3 pending office actions are shared among 3 distinct examiners. This suggests a diversified prosecution strategy where no single examiner dominates the company's active docket. Because each of the 3 distinct examiners handles 1 busiest examiner pending office action, the company must adapt to 3 different sets of examiner preferences and backgrounds.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAGHU, GANAPATHIRAM | 1 | 73.6% | +26.4% |
| YU, TIAN NMN | 1 | 55.1% | +20.4% |
| EVANS, CHRISTOPHER RYAN | 1 | 60.9% | +64.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17793171 | ACTIVITY-SPECIFIC CELL ENRICHMENT | EVANS, CHRISTOPHER RYAN | 70d |
| 18724015 | KNOCKOUT OF ptsP GENE ELEVATES ACTIVE GENE EXPRESSION | RAGHU, GANAPATHIRAM | — |
| 18606513 | COMPOSITION OF TRANSFER RNAS AND USE IN PRODUCTION OF PROTEINS CONTAINING NON-STANDARD AMINO ACIDS | YU, TIAN NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17793171 | ACTIVITY-SPECIFIC CELL ENRICHMENT | EVANS, CHRISTOPHER RYAN | 70d |
| 18724015 | KNOCKOUT OF ptsP GENE ELEVATES ACTIVE GENE EXPRESSION | RAGHU, GANAPATHIRAM | — |
| 18606513 | COMPOSITION OF TRANSFER RNAS AND USE IN PRODUCTION OF PROTEINS CONTAINING NON-STANDARD AMINO ACIDS | YU, TIAN NMN | — |
| Art Unit | Apps |
|---|---|
| 1656 | 2 |
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18724015 | KNOCKOUT OF ptsP GENE ELEVATES ACTIVE GENE EXPRESSION | RAGHU, GANAPATHIRAM | 1656 | §102§103§112 | Non-Final OA | — | Pending | Jun 25, 2024 |
| 18606513 | COMPOSITION OF TRANSFER RNAS AND USE IN PRODUCTION OF PROTEINS CONTAINING NON-STANDARD AMINO ACIDS | YU, TIAN NMN | 1656 | §102§112 | Non-Final OA | — | Pending | Mar 15, 2024 |
| 17793171 | ACTIVITY-SPECIFIC CELL ENRICHMENT | EVANS, CHRISTOPHER RYAN | 1677 | §102§103 | Non-Final OA | 70d | Pending | Jul 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial